What Viehbacher sees in Genzyme
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis's proposed acquisition of Genzyme, announced on 29 August, is a major acceleration of its diversification strategy, which has also seen the company building a presence in the consumer, generics and animal health markets. Simon King explains why Christopher Viehbacher, Sanofi's CEO, is wooing the industry's leading niche market player.